This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Bet on These 4 Low-Beta Stocks to Combat Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Erie Indemnity (ERIE), Sprouts Farmers (SFM), Newmont (NEM) & Calavo (CVGW) are well-poised to gain.
Down -19.96% in 4 Weeks, Here's Why You Should You Buy the Dip in Calavo (CVGW)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Calavo (CVGW) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Best Income Stocks to Buy for July 8th
by Zacks Equity Research
ASIX, CVGW and SM made it to the Zacks Rank #1 (Strong Buy) income stocks list on July 8, 2024.
Limoneira (LMNR) Tops Q2 Earnings Estimates
by Zacks Equity Research
Limoneira (LMNR) delivered earnings and revenue surprises of 109.52% and 18.33%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
New York Times Co. (NYT) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
New York Times (NYT) delivered earnings and revenue surprises of 72.22% and 0.57%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Alico (ALCO) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Alico (ALCO) delivered earnings and revenue surprises of 285.71% and 55.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Predict a 49.55% Upside in Calavo (CVGW): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 49.6% upside potential for Calavo (CVGW). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Chewy (CHWY) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Chewy (CHWY) delivered earnings and revenue surprises of 36.36% and 0.56%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?
Local Bounti Corporation (LOCL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Local Bounti Corporation (LOCL) delivered earnings and revenue surprises of 56.03% and 3.26%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in Calavo Growers (CVGW) Stock?
by Zacks Equity Research
Investors need to pay close attention to Calavo Growers (CVGW) stock based on the movements in the options market lately.
New Strong Sell Stocks for June 9th
by Zacks Equity Research
CVGW, CFG and DCOM have been added to the Zacks Rank #5 (Strong Sell) List on June 9, 2023.
Local Bounti Corporation (LOCL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Local Bounti Corporation (LOCL) delivered earnings and revenue surprises of 8% and 0.53%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Calavo Growers (CVGW) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Calavo (CVGW) delivered earnings and revenue surprises of -133.33% and 18.21%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
Medifast (MED) Readies for Q4 Earnings: Everything to Note
by Zacks Equity Research
Medifast's (MED) fourth-quarter results are likely to reflect the adverse impacts of increased cost inflation, while strength in the OPTAVIA lifestyle solution and coaching support system bodes well.
Factors Influencing Coca-Cola Europacific's (CCEP) Q4 Earnings
by Zacks Equity Research
Despite inflation and supply-chain headwinds, Coca-Cola Europacific's (CCEP) Q4 results are expected to reflect gains from consumer demand and digital growth.
Factors Likely to Influence Crocs' (CROX) Earnings in Q4
by Zacks Equity Research
Despite inflation and supply-chain headwinds, Crocs' (CROX) Q4 results are expected to reflect gains from consumer demand and digital growth.
S&W Seed (SANW) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
S&W Seed (SANW) delivered earnings and revenue surprises of -8.33% and 9.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
TreeHouse Foods (THS) Lined Up for Q4 Earnings: Things to Note
by Zacks Equity Research
TreeHouse Foods' (THS) fourth-quarter 2022 results might reflect gains from efficient pricing actions and cost-control actions.
Brand & Online Strength to Aid Ralph Lauren's (RL) Q3 Earnings
by Zacks Equity Research
Despite freight and currency woes, Ralph Lauren's (RL) Q3 performance is likely to have gained from brand strength and digital growth.
Things to Know Before Hain Celestial's (HAIN) Q2 Earnings
by Zacks Equity Research
Hain Celestial's (HAIN) second-quarter fiscal 2023 results might have been hurt by high inflation, adverse foreign currency translations and supply-chain shortages.
Delta Apparel (DLA) Queued for Q1 Earnings: Factors to Note
by Zacks Equity Research
Delta Apparel's (DLA) first-quarter results are likely to reflect the impacts of a challenging operating backdrop with inflationary pressures.
What's in Store for International Flavors' (IFF) Q4 Earnings?
by Zacks Equity Research
International Flavors' (IFF) Q4 results are likely to reflect the impacts of lower volumes and escalating costs.
New Strong Sell Stocks for January 6th
by Zacks Equity Research
CALT, CVGW and DFH have been added to the Zacks Rank #5 (Strong Sell) List on January 6, 2023.
Calavo Growers (CVGW) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Calavo (CVGW) delivered earnings and revenue surprises of -91.89% and 20.11%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?
Limoneira (LMNR) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Limoneira (LMNR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.